SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Anavex Life Sciences Corp (OTCMKTS:AVXL), a renowned clinical stage biopharmaceutical company known for offering drugs to treat Alzheimer’s disease, has decided to make certain changes in its board of directors. As per the reports, the biggest of the changes made by the company is the addition of Steffen Thomas in BOD.

Insights On The Matter:

Dr. Thomas comes with a massive experience of 15 years in patent law, intellectual property, proprietary technology rights and small molecule pharmaceuticals. Under his guidance, Anavex looks forward to performing well in the market.

Currently, he works as a patent attorney, European trademark attorney and European patent attorney at a major European intellectual property law firm named Epping Hermann Fischer. Before joining Anavex Life Sciences, he was associated with Takeda Pharmaceutical Company, the largest Asian pharmaceutical company based in Japan. It is also considered as one of the largest companies in the world. He was an in-house patent attorney at that firm.

Dr. Thomas had worked for Nycomed Pharma before it was acquired by Takeda for $10 billion in 2011. His legal practices comprise of drafting and prosecuting patent applications before domestic and international patent offices, challenging and defending patents in opposition, etc. Apart from this, he also looks after nullity proceedings, appeal, enforcing patents in the infringement courts, and preparing various opinions on infringement and patentability in Chemistry field.

The senior management of Anavex is pleased to have him on board and hopes that the company will perform well under his solid guidance. According to Christopher U. Missling, Chief Executive Officer & President, Anavex Life Sciences Corp (OTCMKTS:AVXL), it’s great to have Dr. Thomas as part of company’s board. The management team believes that his expertise in the pharmaceutical industry and intellectual property rights will prove to be beneficial for Anavex in the future.

The company is slowly broadening its pipeline of products and services, and his presence will help it doing so in an effective manner.